Genmab — Maj 2015
-
der kommer safety issues ved 2,2 mg. men ingenting ved 1,8 så de regner med at 2,0 bliver den valgte MTD
-
men det er også hvad man har set andre ADC stoffer anvende så vidt jeg ved, så ikke den store forskel der
-
Earlier this month, Johnson & Johnson (NYSE:JNJ) announced plans to file applications by the end of this year for U.S. and European regulatory approval of daratumumab as a new treatment for relapsed multiple myeloma. The updated trial results released this morning will support those applications, which could result in daratumumab becoming available to treat myeloma patients outside of clinical trials by the first half of next year. http://www.myelomabeacon.com/news/2015/05/30/daratumumab-multip
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind